Table 2.
Findings of analyses of covariance to investigate the effect of hepatitis C virus (HCV) antibody status and HCV RNA status on the number and percentage of T cell subsets in 218 women, by human immunodeficiency virus type 1 (HIV-1) infection status.
| HIV+ |
HIV− |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variable | HCV+RNA+ | HCV+RNA− | HCV− | HCV+RNA+ effect | Pa | HCV+RNA− effect | Pa | HCV+RNA+ | HCV+RNA− | HCV− | HCV+RNA+ effect | Pa | HCV+RNA− effect | Pa |
| Activation markers | ||||||||||||||
| No. of subjects | 52 | 16 | 101 | … | … | 11 | 4 | 34 | … | … | ||||
| CD4+HLA-DR+38+ cells | ||||||||||||||
| Count, cells/mm3 | 56 ± 13 | 33 ± 19 | 44 ± 13 | 12 ± 16 | .68 | −11 ± 21 | .27 | 23 ± 24 | 10 ± 31 | 45 ± 19 | −22 ± 31 | .26 | −35 ± 37 | .18 |
| Percentage | 16.1 ± 4.1 | 14.3 ± 5.8 | 9.7 ± 4.2 | 6.4 ± 5.0 | .23 | 4.5 ± 6.6 | .58 | 2.3 ± 1.5 | 1.0 ± 1.9 | 3.3 ± 1.1 | −1.0 ± 1.9 | .41 | −2.3 ± 2.2 | .19 |
| CD8+HLA-DR+38+ cells | ||||||||||||||
| Count, cells/mm3 | 326 ± 70 | 264 ± 99 | 167 ± 71 | 159 ± 86 | .07 | 97 ± 112 | .28 | 24 ± 30 | 2 ± 38 | 27 ± 23 | −3 ± 38 | .59 | −25 ± 45 | .24 |
| Percentage | 30.7 ± 4.1 | 26.4 ± 6.8 | 13.8 ± 4.9 | 16.9 ± 5.9 | .008 | 12.6 ± 7.7 | .17 | 2.6 ± 2.9 | −0.6 ± 3.7 | 4.4 ± 2.3 | −1.8 ± 3.7 | .28 | −5.1 ± 4.4 | .05 |
| CD8+CD28+ markers on subset | ||||||||||||||
| No. of subjects | 35 | 10 | 34 | … | … | 5 | 1 | 14 | … | … | ||||
| CD8+CD28+ cells | ||||||||||||||
| Count, cells/mm3 | 407 ± 57 | 333 ± 88 | 440 ± 70 | −33 ± 91 | .69 | −107 ± 113 | .36 | 561 ± 132 | 770 ± 229 | 471 ± 85 | 90 ± 179 | .33 | 299 ± 251 | .14 |
| Percentage | 39.3 ± 4.4 | 27.3 ± 6.8 | 43.8 ± 5.4 | −4.5 ± 7.1 | .60 | −16.5 ± 8.8 | .07 | 77.1 ± 12.8 | 82.2 ± 22.1 | 67.9 ± 8.2 | 9.2 ± 17.3 | .67 | 14.3 ± 24.3 | .64 |
| CD8+CD28+HLA-DR+ cells | ||||||||||||||
| Count, cells/mm3 | 201 ± 38 | 158 ± 59 | 140 ± 47 | 62 ± 61 | .11 | 18 ± 76 | .32 | 59 ± 40 | 114 ± 69 | 57 ± 25 | 2 ± 54 | .83 | 57 ± 75 | .38 |
| Percentage | 19.0 ± 2.1 | 15.1 ± 3.3 | 12.8 ± 2.6 | 6.2 ± 3.4 | .01 | 2.3 ± 4.3 | .14 | 7.0 ± 3.6 | 11.3 ± 6.3 | 7.6 ± 2.3 | −0.6 ± 4.9 | .89 | 3.6 ± 6.9 | .59 |
| CD8+CD28+HLA-DR+ cells | ||||||||||||||
| Count, cells/mm3 | 206 ± 34 | 175 ± 52 | 300 ± 42 | −94 ± 54 | .08 | −125 ± 67 | .06 | 502 ± 109 | 655 ± 190 | 414 ± 70 | 88 ± 148 | .31 | 242 ± 208 | .16 |
| Percentage | 20.3 ± 3.8 | 12.3 ± 59 | 31.0 ± 4.7 | −10.7 ± 6.1 | .18 | −18.8 ± 7.6 | .03 | 70.1 ± 13.0 | 71.0 ± 22.5 | 60.3 ± 8.3 | 9.8 ± 17.6 | .60 | 10.6 ± 24.7 | .64 |
NOTE. Data are adjusted mean values ± SE. Two of 220 women originally enrolled were excluded from the analysis because of indeterminate results of HCV RNA tests. HCV+, HCV antibody positive; HCV−, HCV antibody negative; HIV+, HIV-1 positive; HIV−, HIV-1 negative; RNA+, HCV RNA positive; RNA−, HCV RNA negative.
Estimated on the basis of analyses of covariance that used ranked data, with adjustment for age group (<30, 30–39, or ⩾40 years), race (black, white non-Hispanic, Hispanic, or other), injection drug use (yes or no), and HIV-1 treatment (any antiretroviral therapy or no antiretroviral therapy)